| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b/2a data readout example | Phase 1b/2a | — | Subscribe to access the data. | Biologics | Hematologic System | ||
Phase 1b/2a data readout example | Phase 1b/2a | — | Subscribe to access the data. | Biologics | Hematologic System | ||
Phase 1b/2a data readout example | Phase 1b/2a | — | Subscribe to access the data. | Biologics | Hematologic System |
Recent Updates
Recently added Catalysts
Climb Bio, Inc.$14
+0.18 (+1.3%)
C 43Pipeline Score Fair Value Biotech · Commercial
Market Cap
629.87 M
EPS
-0.78
P/E Ratio
-
Value Trade
13.87 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
9.37 M
Operating CF
-14.38 M
Total Assets
152.37 M
Total Liabilities
4.29 M
Equity
148.09 M
D/E Ratio
12,345
-0.36 %
Week
16.28 %
1 Month
97.13 %
3 Month
539.53 %
6 Month
-32.31 %
5 Year
-32.31 %
All Time
Cash Data
Cash Position
109.56 M
Monthly Burn
4.79 M
Runway
21 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
1.25 M
52 Week Range
1.16 - 12.48
% held by Insiders
14.08 %
% held by Institutions
73.56 %
Enterprise Value
520.78 M
Total Shares
47.73 M
Short %
25.54 %
Float Shares
19.95 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Climb Bio, Inc.
184Total events
3Upcoming
34Tier-1 (high impact)
2021 – 2028Coverage
Upcoming catalysts 3
Event history 181
Jun 13, 2026
◆Poster PresentationBudoprutugPresentation
Poster presentation of initial Phase 1b study results for budoprutug in ITP at EHA 2026
primary immune thrombocytopeniasource ↗
Jun 11, 2026
▲Poster PresentationBudoprutugPresentation
Initial Phase 1b data presented at EHA Congress 2026
immune thrombocytopeniasource ↗
Jun 11, 2026
◆Enrollment UpdateBudoprutugTrial
Enrollment ongoing in 1000 mg cohort
immune thrombocytopeniasource ↗
Jun 5, 2026
◆Oral PresentationCLYM116Presentation
Focused oral presentation on CLYM116 PK/PD modeling and initial Phase 1 safety data at ERA 2026
IgA nephropathysource ↗
Jun 4, 2026
◆Poster PresentationBudoprutugPresentation
Trial-in-progress poster for PrisMN Phase 2 study of budoprutug in pMN at ERA 2026
primary membranous nephropathysource ↗
Jun 2026
◆Topline ReadoutBudoprutugClinical Data
Initial data from ITP trial anticipated
immune thrombocytopenia (ITP)source ↗
Jun 2026
◆Biomarker DataCLYM116Clinical Data
Initial biomarker and dosing interval data anticipated mid-year 2026
IgA nephropathysource ↗
Jun 2026
◆Oral PresentationCLYM116Presentation
Presentation of modeling data and initial Phase 1 safety data at ERA 2026
IgA nephropathysource ↗
Jun 2026
◆Topline ReadoutCLYM116Clinical Data
Initial healthy volunteer data for CLYM116 expected mid-2026
healthy volunteerssource ↗
May 5, 2026
Drug Pipeline Intelligence
C43
Pipeline Score $211M
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored1.1x
rNPV / MCap Top 63%
Micro Cap (rank 338 of 911)
Percentile RankClimb Bio, Inc. carries a moderate pipeline score (43/100), with $855M risk-adjusted pipeline value, led by Budoprutug in Systemic Lupus Erthematosus (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| budoprutug Small molecule | Primary Membranous Nephropathy | Phase 2 | NCT07096843 | 27% | $398M | RECRUITING | 45 | AVERAGE | D (34) | Oct 1, 2027 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
budoprutug Fast TrackOrphan | primary immune thrombocytopenia | Phase 1b | 2026-06-11 | 15 patients had been enrolled across the 250 mg (n=6) and 500 mg (n=9) dose cohorts; median follow-up was 38 weeks and 12 weeks for the 250 mg and 500 mg cohorts respectively; B-cell levels were depleted by an average of over 90% by Week 4; mean platelet count increased by 111,000 platelets/µL at Week 24; Durable platelet responses were achieved in four out of six patients in the 250 mg dose cohort; two out of six patients experiencing platelet levels >100 x 103/µL for over 24 weeks; Of the four patients who had previously been treated with rituximab, three responded to treatment with budoprutug, two with durable and complete responses Read More | Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026 Read More | |
budoprutug Fast TrackOrphan | primary immune thrombocytopenia | Phase 1b | 2026-06-11 | 15 patients had been enrolled across the 250 mg (n=6) and 500 mg (n=9) dose cohorts; median follow-up was 38 weeks and 12 weeks for the 250 mg and 500 mg cohorts respectively; B-cell levels were depleted by an average of over 90% by Week 4; mean platelet count increased by 111,000 platelets/µL at Week 24; Durable platelet responses were achieved in four out of six patients in the 250 mg dose cohort; two out of six patients experiencing platelet levels >100 x 103/µL for over 24 weeks; Of the four patients who had previously been treated with rituximab, three responded to treatment with budoprutug, two with durable and complete responses Read More | Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026 Read More | |
budoprutug Fast TrackOrphan | primary immune thrombocytopenia | Phase 1b | 2026-06-11 | 15 patients had been enrolled across the 250 mg (n=6) and 500 mg (n=9) dose cohorts; median follow-up was 38 weeks and 12 weeks for the 250 mg and 500 mg cohorts respectively; B-cell levels were depleted by an average of over 90% by Week 4; mean platelet count increased by 111,000 platelets/µL at Week 24; Durable platelet responses were achieved in four out of six patients in the 250 mg dose cohort; two out of six patients experiencing platelet levels >100 x 103/µL for over 24 weeks; Of the four patients who had previously been treated with rituximab, three responded to treatment with budoprutug, two with durable and complete responses Read More | Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CLYM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CLYM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CLYMClimb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
Climb Bio announced initial Phase 1b data for budoprutug, showing a favorable safety profile and significant B-cell depletion in patients with primary immune thrombocytopenia (ITP). The data, presented at the EHA Congress 2026, indicate promising platelet responses, especially in patients previously treated with rituximab. Enrollment in the study's high-dose cohort is ongoing, with further data expected by the end of 2026.
Read more →CLYMCLIMB BIO, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS
Climb Bio, Inc. has adopted a new Equity Incentive Plan as approved by the Compensation Committee of the Board of Directors. This plan is a continuation of the previous plan and is designed to secure and retain talent, including employees, directors, and consultants. It allows for various award types such as Incentive Stock Options and Restricted Stock Awards, with a total of approximately 5.2 million shares available. The plan is structured to provide annual increases in shares awarded over the next decade to continually engage and incentivize eligible participants.
Read more →CLYMClimb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
Read more →CLYMClimb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
Climb Bio, Inc. will present its CLYM116 and budoprutug programs at the European Renal Association Congress 2026 in Glasgow. The presentations will include pharmacokinetic modeling and initial safety data from the CLYM116 Phase 1 study, as well as a trial-in-progress poster for the Phase 2 study of budoprutug in primary membranous nephropathy. These developments reflect Climb Bio's commitment to addressing immune-mediated diseases.
Read more →CLYMClimb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
Climb Bio, Inc. will present new clinical data on its budoprutug program at the EHA 2026 Congress in Stockholm. The data will include safety and efficacy results from a Phase 1b/2a trial focusing on patients with immune thrombocytopenia. Budoprutug, an anti-CD19 monoclonal antibody, has shown promise in treating various B-cell mediated diseases.
Read more →CLYMClimb Bio to Present at Upcoming Investor Conferences
Climb Bio to Present at Upcoming Investor Conferences
Read more →CLYMClimb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM1
Climb Bio, Inc. has reported its financial results for the first quarter of 2026, highlighting significant advancements in its clinical programs. The company observed robust B-cell depletion in trials for budoprutug, an anti-CD19 monoclonal antibody, and secured $110 million in new financing. Ongoing trials for budoprutug in primary membranous nephropathy and immune thrombocytopenia are on track, with key data expected throughout 2026. Additionally, progress in the CLYM116 program is set to be presented at the European Renal Association Congress in June 2026.
Read more →CLYM▲ +18.2%on this newsshared move
CONFIDENTIAL Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts Robust B-cell depletion observed with
Climb Bio, Inc. has announced promising updates on budoprutug, an anti-CD19 monoclonal antibody targeting B-cell mediated diseases. At a recent R&D Spotlight event, the company showcased positive topline data from a subcutaneous formulation trial, indicating robust B-cell depletion in healthy volunteers. Budoprutug is currently undergoing clinical trials for primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, with Fast Track Designation granted for pMN. The company anticipates initial data releases from trials in the near future, highlighting a significant opportunity within the immune-mediated disease landscape.
Read more →CLYM▲ +18.2%on this newsshared move
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-cell Mediated Disease Opportunity, and Upcoming Data Readouts
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-cell Mediated Disease Opportunity, and Upcoming Data Readouts
Read more →CLYMClimb Bio, Inc. Announces $110.0 Million Private Placement
Climb Bio, Inc. has announced a private placement of approximately $110 million with institutional investors. The placement involves selling 9,481,000 shares of common stock at $9.50 each, along with pre-funded warrants. The proceeds will support the company's development of therapeutics for immune-mediated diseases. The closing is expected on April 29, 2026, pending customary conditions.
Read more →CLYMClimb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
Climb Bio, Inc. will host a webcast on May 5, 2026, focusing on its budoprutug program, which targets B-cell mediated diseases. The event will feature insights on the clinical potential of budoprutug in treating conditions like primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. The webcast will also discuss ongoing studies and the company's development strategy.
Read more →CLYMClimb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
Read more →CLYMClimb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Climb Bio reported its fourth quarter and full year 2025 financial results, highlighting a strong cash position expected to fund operations into 2028. The company has completed dosing in a Phase 1 study of budoprutug's subcutaneous formulation and is conducting multiple trials for this and CLYM116. Initial data from these trials is anticipated in 2026.
Read more →CLYM▲ +9%on this news· ran to +20% by day 1
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a
Climb Bio has announced significant progress in its pipeline and strategic plans for 2026, including the dosing of first patients in the budoprutug Phase 2 trial for primary membranous nephropathy. The company highlighted its strong financial position, expecting cash resources to last until 2028, and indicated a data-rich year ahead with several trial readouts anticipated. Climb Bio's achievements include obtaining 20 regulatory approvals for clinical trials and advancing its other candidate, CLYM116, into the clinic. Ongoing trials are aimed at addressing unmet needs in immune-mediated diseases.
Read more →CLYMIN THE SUPERIOR COURT OF THE STATE OF DELAWARE CLIMB BIO, INC., ) ) Plaintiff, ) v. ) ) C.A. No. ________CCLD ALUMIS INC., and ACELYRIN, ) INC. (a wholly owned subsidiary), ) ) Defendant. ) COMPLAINT Plaintiff Climb Bio,
Climb Bio, Inc. has filed a lawsuit against Alumis Inc. and Acelyrin, Inc. in Delaware, seeking clarification on contractual obligations under an Asset Purchase Agreement related to the budoprutug drug candidate. Climb argues that no Royalty-Bearing Patents were transferred under the agreement and asserts it owes no payments to Alumis. The dispute arises as Alumis demands a $3 million milestone payment, claiming rights to profits from Climb's independent development of the drug. The legal proceedings highlight significant contractual disagreements between the parties.
Read more →CLYMClimb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Climb Bio, Inc. has announced the granting of an inducement equity award under Nasdaq Listing Rule 5635(c)(4) to a new employee. This inducement includes a stock option to purchase 120,000 shares of common stock at an exercise price of $1.76 per share, which matches the closing price on the grant date. The option vests over four years, aligning employee retention with company success. Climb Bio focuses on developing therapeutics for immune-mediated diseases and is currently advancing its therapeutic pipeline.
Read more →CLYMClimb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Climb Bio reported its third quarter 2025 financial results, highlighting the initiation of several clinical trials for its drug candidates, budoprutug and CLYM116. The company has strengthened its leadership team and expects a cash runway through 2027. Initial data from ongoing trials is anticipated in 2026, marking a pivotal year for the company.
Read more →CLYMClimb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
Climb Bio has appointed Adam Villa as SVP of Technical Operations and Ashley Jones as SVP of People & Workforce Strategy. These appointments are aimed at enhancing operational efficiency and advancing clinical development plans for their therapeutic programs. Both executives bring extensive experience in biopharmaceutical development and organizational leadership.
Read more →CLYMClimb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
Climb Bio, Inc. will present preclinical data for CLYM116 and long-term data for budoprutug at the ASN Kidney Week 2025. CLYM116 is an anti-APRIL monoclonal antibody aimed at treating IgA nephropathy, while budoprutug has shown potential benefits in primary membranous nephropathy. The data supports further investigation into both therapies.
Read more →CLYMClimb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
Climb Bio has appointed Susan Altschuller, Ph.D., MBA, as Chief Financial Officer, bringing over two decades of experience in biopharmaceutical finance. Her leadership is expected to support the company's advancement of its therapeutic pipeline, including budoprutug and CLYM116. The company anticipates generating significant clinical data in the coming year.
Read more →CLYM▼ -6.6%on this newsshared move
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
Climb Bio announced promising preclinical data for CLYM116, an anti-APRIL monoclonal antibody, demonstrating improved IgA reduction and longer half-life compared to existing therapies. The company plans to initiate a Phase 1 trial in Q4 2025, with initial data expected by mid-2026. This development highlights the potential for CLYM116 to address the unmet needs in IgA nephropathy treatment.
Read more →CLYMClimb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
Climb Bio, Inc. will host a webcast on September 29, 2025, to discuss its CLYM116 program targeting IgA nephropathy. The event will feature insights from nephrologist Craig E. Gordon and highlight CLYM116's unique mechanism of action as a monoclonal antibody. Climb Bio plans to file an IND or CTA for CLYM116 in the latter half of 2025.
Read more →CLYMUPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
Read more →CLYMClimb Bio to Present at Upcoming September 2025 Investor Conferences
Climb Bio, Inc. has announced participation in several upcoming investor conferences in September 2025, including the Cantor Global Healthcare Conference and the Baird Global Healthcare Conference. The events will be held in New York, featuring a combination of fireside chats and one-on-one meetings. These conferences provide Climb Bio an opportunity to present its work on therapies for immune-mediated diseases, including the promising anti-CD19 monoclonal antibody, budoprutug. The company aims to increase its visibility in the investment community during these strategic engagements.
Read more →CLYMClimb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in
Climb Bio has reported its second quarter 2025 financial results and detailed updates on the clinical progress of its lead drug, budoprutug, which is currently in trials for immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE). The company anticipates starting a Phase 2 trial for primary membranous nephropathy (pMN) soon, alongside a Phase 1 trial for a subcutaneous formulation of budoprutug. Additionally, Climb Bio has announced plans to host an investor event in September 2025 featuring new preclinical data and developments related to CLYM116, its anti-APRIL monoclonal antibody targeting IgA nephropathy (IgAN). The company maintains a strong cash position to support ongoing operations through 2027.
Read more →CLYMClimb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
Climb Bio, a clinical-stage biotechnology company, has appointed Dr. Edgar D. Charles as Chief Medical Officer and Cindy J. Driscoll as Senior Vice President of Finance. Dr. Charles brings over 20 years of experience in immunology drug development, while Driscoll has a strong background in financial operations within the biopharma sector. Their appointments come as the company looks to advance its pipeline, particularly the clinical studies of budoprutug and CLYM116. The leadership expansion is seen as pivotal for the company as it seeks to maximize the therapeutic potential of its promising programs.
Read more →CLYM▼ -7.9%on this newsshared move
Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus
Climb Bio, Inc. reported its financial results for Q1 2025, highlighting progress in clinical trials for budoprutug, an anti-CD19 monoclonal antibody, targeting various immune-mediated diseases. The company received FDA clearances to initiate trials for budoprutug in patients with primary membranous nephropathy and immune thrombocytopenia, with studies anticipated to commence later in 2025. Climb Bio also plans to submit investigational new drug applications for CLYM116, another promising candidate. Its financial position remains robust, with sufficient cash reserves to support operations through 2027.
Read more →CLYMClimb Bio Appoints Seasoned Biotech Leaders to Board of Directors
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
Read more →CLYMClimb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
Read more →CLYMClimb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membrano
Climb Bio, Inc. reported its financial results for the fourth quarter and year ended December 31, 2024, highlighting significant progress in its drug development pipeline. The company received FDA clearance to initiate clinical trials for its lead candidate, budoprutug, targeting primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. Climb Bio also expanded its pipeline with a new asset, CLYM116, aimed at treating IgA nephropathy. The company concluded 2024 with a robust financial position and anticipates continuing momentum into 2025 amidst several operational challenges.
Read more →CLYMClimb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer
Climb Bio, Inc. has appointed Perrin Wilson, Ph.D., as its new Chief Business Officer, capitalizing on her over 17 years of experience in the pharmaceutical and biotech sectors. Dr. Wilson's leadership will focus on the company's pre-commercial planning, communications, and business development. She is expected to play a critical role in progressing Climb Bio's innovative treatments for immune-mediated diseases, including budoprutug and CLYM116. The appointment comes at a time when the company seeks to strengthen its position in the rapidly evolving biotech landscape.
Read more →CLYM▼ -6%on this news
Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Read more →CLYM▲ +7%on this news
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
Read more →CLYMClimb Bio to be Added to the Nasdaq Biotechnology Index
Climb Bio to be Added to the Nasdaq Biotechnology Index
Read more →CLYM▼ -6.4%on this news· ran to -26% by day 3
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic
Climb Bio, Inc. reported its third-quarter 2024 financial results, highlighting the recent FDA clearance of an IND for budoprutug, its lead candidate targeting systemic lupus erythematosus. The company expanded its management team by appointing Douglas Williams, Ph.D., as the Chair of the Board and Gary Hao, Ph.D., as Vice President of Chemistry, Manufacturing and Controls. Financially, Climb Bio holds a strong cash position projected to last through 2027, though it reported a net loss of $8.9 million for the quarter, reflecting increased research and administrative expenses.
Read more →CLYM▲ +7.1%on this newsshared move
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
Read more →CLYM▼ -6.3%on this news
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membran
Climb Bio, Inc. announced its strategy for the development of budoprutug, an anti-CD19 monoclonal antibody aimed at treating immune-mediated diseases, during a virtual investor event. The company highlighted additional data from its recent Phase 1b study focused on primary membranous nephropathy, noting significant clinical remission rates among trial participants. Plans were also outlined for upcoming clinical trials in systemic lupus erythematosus and immune thrombocytopenia, projected to commence in the first half of 2025. With a cash runway extending through 2027, Climb Bio is poised for key milestones in its development trajectory.
Read more →CLYM▲ +5.4%on this newsshared move
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
Read more →CLYMClimb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
Climb Bio, Inc. (Nasdaq: CLYM) will present and host investor meetings at the upcoming William Blair event focused on transforming autoimmune diseases through CD19 targeting. This event is scheduled for October 16, 2024, in New York, NY. Climb Bio is a clinical-stage biotechnology company known for its development of therapeutics for immune-mediated diseases, with its lead candidate, budoprutug, being an anti-CD19 monoclonal antibody.
Read more →CLYMClimb Bio to Host Virtual Investor Event on October 15, 2024
Climb Bio, Inc. announced it will host a virtual investor event on October 15, 2024, featuring key management members and an external expert. The presentations will focus on the company's strategy and its lead product candidate, budoprutug, an anti-CD19 monoclonal antibody aimed at treating immune-mediated diseases. The event will also provide insights from prominent figures in the field, including a key opinion leader. Registration for the event is available online, with a live webcast and replay offered on the company's website.
Read more →CLYMEliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
Read more →CLYMEliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
Read more →CLYMEliem Therapeutics Announces Additions to its Leadership Team
Eliem Therapeutics Announces Additions to its Leadership Team
Read more →CLYMEliem Therapeutics, Inc. Condensed Consolidated Balance Sheets (In thousands) (unaudited)
Eliem Therapeutics has reported its financial results for the second quarter of 2024, highlighting a substantial net loss and the successful completion of its acquisition of Tenet Medicines. The company has positioned itself to advance its lead candidate, budoprutug, targeting several underserved autoimmune diseases and expects to continue its operations through 2027 supported by a strong cash position. Eliem plans an Investor Day later this year to detail its development strategy and upcoming milestones. The leadership changes within the company may bring additional expertise to advance its objectives.
Read more →CLYMEliem Therapeutics Reports Second Quarter Financial Results
Eliem Therapeutics Reports Second Quarter Financial Results
Read more →CLYMEliem Therapeutics Announces its Addition to the Russell 2000 and Russell 3000 Indexes
Eliem Therapeutics Announces its Addition to the Russell 2000 and Russell 3000 Indexes
Read more →CLYMEliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of au
Eliem Therapeutics has successfully completed its acquisition of Tenet Medicines, facilitating its focus on advancing TNT119, an anti-CD19 antibody targeting autoimmune diseases. The acquisition is complemented by a $120 million private placement, resulting in a total cash reserve of approximately $220 million, expected to support operations until 2027. The company plans to initiate Phase 2 clinical trials for TNT119 later this year, aiming to address systemic lupus erythematosus and other conditions. Key executive appointments were also made to bolster leadership and strategic direction following the acquisition.
Read more →CLYMEliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated dis
Eliem Therapeutics has announced an acquisition agreement for Tenet Medicines, focusing on the development of TNT119, an anti-CD19 antibody for autoimmune diseases. The deal includes a $120 million private placement to finance this initiative. The combined company is projected to have approximately $210 million in cash, sufficient to fund operations into 2027. Eliem plans to initiate Phase 2 trials for systemic lupus erythematosus and immune thrombocytopenia, aiming to address significant unmet medical needs in these areas.
Read more →CLYMSUMMARY OF PROPOSED TERMS FOR TRANSACTION BETWEEN ELIEM THERAPEUTICS, INC. AND [TARGET] Form of Transaction: Eliem Therapeutics, Inc. ( Eliem ) will acquire 100% of the outstanding equity interests of [TARGET] ( Tango )
Eliem Therapeutics, Inc. has proposed to acquire 100% of the outstanding equity interests of Tango. The transaction is structured as a tax-free reorganization with an exchange ratio that values Tango at $20 million. Following the acquisition, Tango's equity holders will own 15.4% of the combined entity, while Eliem's shareholders will hold 84.6%. A concurrent private placement of equity interests is also planned to support the transaction. Final completion of the deal is subject to standard due diligence and board approvals from both companies.
Read more →CLYMEliem Therapeutics Announces Plans to Explore Strategic Alternatives SEATTLE and CAMBRIDGE, UK, (GLOBE NEWSWIRE)
Eliem Therapeutics has decided to halt development of its Kv7 program while it explores strategic alternatives to enhance shareholder value. The company has engaged Leerink Partners to assist in this process, which may involve various transactions including acquisitions or mergers. With about $102.6 million in cash and equivalents, Eliem is assessing its options without a fixed timeline for the evaluation.
Read more →CLYMEliem Therapeutics Reports First Quarter Financial Results and Business Highlights Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the
Eliem Therapeutics reported its first-quarter financial results, highlighting promising initial preclinical data for ETX-123, its lead candidate targeting Kv7 channels. The data shows ETX-123's high potency and confirms its mechanism of action in modulating neuronal excitability. Financially, the company maintains a strong balance sheet, with sufficient funds projected to last until 2027, despite experiencing a significant net loss this quarter attributed to restructuring costs. Future data presentations are scheduled at scientific conferences later this year.
Read more →CLYMEliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemen
Eliem Therapeutics reported its fourth quarter and year-end financial results, highlighting progress in its IND-enabling studies for ETX-123 and the Kv7.2/3 channel opener program. The company has undergone a corporate reorganization, focusing its resources on the Kv7 program while pausing development of its other candidate, ETX-155. With a cash position extended into 2027, Eliem plans to initiate Phase 1 studies for ETX-123 in the first half of 2024. However, the reorganization will result in a significant workforce reduction of around 55%.
Read more →CLYMEliem Therapeutics Provides Strategic Update and Announces Leadership Transition
Eliem Therapeutics has provided an update that includes a strategic shift to focus on its Kv7.2/3 channel opener program while pausing development of its candidate ETX-155 for Major Depressive Disorder due to adverse capital market conditions. The company announced a corporate reorganization plan that will reduce its workforce by 55% to extend its financial runway into 2027. Despite these challenges, Eliem plans to advance its lead candidate ETX-123 into a Phase 1 trial by mid-2024, ensuring it retains core R&D talent during the leadership transition.
Read more →CLYMEliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
Read more →CLYMEliem Therapeutics Reports Third Quarter Financial and Business Highlights Positioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose Progressing IND-en
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights Positioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose Progressing IND-enabling studies for two Kv7 pre-candidates with safety stud
Read more →CLYMEliem Therapeutics to Participate at Two Upcoming Investor Conferences
Eliem Therapeutics to Participate at Two Upcoming Investor Conferences
Read more →CLYMEliem Therapeutics Provides Update on Pipeline Progress Company is positioned to initiate Phase 2a trial in major depressive disorder (MDD) in the first quarter of 2023 ETX-155 demonstrating exposures in single dose 60-m
Eliem Therapeutics Provides Update on Pipeline Progress Company is positioned to initiate Phase 2a trial in major depressive disorder (MDD) in the first quarter of 2023 ETX-155 demonstrating exposures in single dose 60-milligram cohorts of ongoing Phase 1 pharmacokinetic trial
Read more →CLYMEliem Therapeutics Reports Second Quarter Financial and Business Highlights Initiated Phase 1 pharmacokinetic trial for ETX-155 with expected results in Q4 2022 Capital now expected to fund operations into 2025 SEATTLE a
Eliem Therapeutics Reports Second Quarter Financial and Business Highlights Initiated Phase 1 pharmacokinetic trial for ETX-155 with expected results in Q4 2022 Capital now expected to fund operations into 2025 SEATTLE and CAMBRIDGE, UK, --(GLOBE NEWSWIRE) August 15, 2022 Elie
Read more →CLYMEliem Therapeutics Provides ETX-810 Program Update
Eliem Therapeutics Provides ETX-810 Program Update
Read more →CLYMEliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder
Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder
Read more →CLYMEliem Therapeutics to Host Virtual Investor Event on July 21, 2022
Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022
Read more →CLYMEliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)
Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)
Read more →CLYMEliem Therapeutics Reports First Quarter Financial and Business Highlights SEATTLE and CAMBRIDGE, UK, --(GLOBE NEWSWIRE) –
Eliem Therapeutics Reports First Quarter Financial and Business Highlights SEATTLE and CAMBRIDGE, UK, --(GLOBE NEWSWIRE) May 16, 2022 Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability d
Read more →CLYMEliem Provides Update on ETX-810 and ETX-155 Clinical Programs
Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs
Read more →CLYMEliem Therapeutics Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs
Eliem Therapeutics Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs
Read more →CLYMClinical Stage Neurology Company Focused on Neuronal Excitability Disorders Corporate Presentation |
Clinical Stage Neurology Company Focused on Neuronal Excitability Disorders Corporate Presentation | Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of histor
Read more →CLYMEliem Therapeutics to Present at Stifel's 2022 CNS Days
Eliem Therapeutics to Present at Stifel's 2022 CNS Days
Read more →CLYMEliem Therapeutics Reports Fourth Quarter and Year-End Financial and Business Highlights Completed dosing in Phase 2a clinical trial of ETX-810 in subjects with diabetic peripheral neuropathic pain; topline data to be pr
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial and Business Highlights Completed dosing in Phase 2a clinical trial of ETX-810 in subjects with diabetic peripheral neuropathic pain; topline data to be presented in 1H 2022 Interim data from Phase 1b clinical tri
Read more →CLYMEliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Eliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Read more →CLYMEliem Therapeutics to Host Virtual Investor Event Featuring Opinion Leaders in Chronic Pain Research on February 16, 2022
Eliem Therapeutics to Host Virtual Investor Event Featuring Opinion Leaders in Chronic Pain Research on February 16, 2022
Read more →CLYMEliem Therapeutics Provides Program Updates and an Overview of Expected Near-Term Milestones
Eliem Therapeutics Provides Program Updates and an Overview of Expected Near-Term Milestones
Read more →CLYMEliem Therapeutics Reports Third Quarter Financial and Business Highlights Advanced ETX-155 clinical development program, with the first subject successfully screened in epilepsy proof-of-concept trial and significant pr
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights Advanced ETX-155 clinical development program, with the first subject successfully screened in epilepsy proof-of-concept trial and significant progress made toward the initiation of major depressive disor
Read more →CLYMEliem Therapeutics to Participate at Four Upcoming Investor Conferences
Eliem Therapeutics to Participate at Four Upcoming Investor Conferences
Read more →CLYMEliem Therapeutics Reports Second Quarter Financial Results On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months Recently complet
Eliem Therapeutics Reports Second Quarter Financial Results On track to advance two clinical programs through five proof-of-concept trials and progress two preclinical programs over the next 18-24 months Recently completed an IPO for $92 million in gross proceeds that, along wi
Read more →CLYMEliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Eliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Read more →CLYMEliem Therapeutics Announces Pricing of Initial Public Offering
Eliem Therapeutics Announces Pricing of Initial Public Offering
Read more →Competitive Position
How CLYM ranks across every disease it competes inCompetitive Position is a premium feature
See how CLYM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial